Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma

British Journal of Haematology

Volumn 167, Issue 1, 2014, Pages 127-131

  Lee, Min Jung ^a   Wickner, Paige ^a   Fanning, Laura ^a   Schlossman, Robert ^b   Richardson, Paul ^b   Laubach, Jacob ^b   Castells, Maria ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allergy; Desensitization; Lenalidomide; Multiple myeloma; Myeloma therapy

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; LENALIDOMIDE; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CASE REPORT; DELAYED HYPERSENSITIVITY; DESENSITIZATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE EDEMA; FEMALE; HEART EJECTION FRACTION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; URTICARIA; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG HYPERSENSITIVITY; HYPERSENSITIVITY, DELAYED; MIDDLE AGED; TREATMENT OUTCOME;

DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84908871598     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12925     Document Type: Article

References (10)

1. Bastuji-Garin, S., Fouchard, N., Bertocchi, M., Roujeau, J.C., Revuz, J. & Wolkenstein, P. (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. The Journal of Investigative Dermatology, 115, 149-153.
2. Cañamares Orbis, I., García Muñoz, C., Cortijo Cascajares, S. & Méndez Esteban, M.E. (2012) Desensitization to lenalidomide. Farmacia Hospitalaria, 36, 542-543. Spanish.
3. McCarthy, P.L., Owzar, K., Hofmeister, C.C., Hurd, D.D., Hassoun, H., Richardson, P.G., Giralt, S., Stadtmauer, E.A., Weisdorf, D.J., Vij, R., Moreb, J.S., Callander, N.S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R.T., Gabriel, D.A., Bashey, A., Landau, H., Martin, T., Qazilbash, M.H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M.C., Horowitz, M.M., Shea, T.C., Devine, S.M., Anderson, K.C. & Linker, C. (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1770-1781.
4. Nardone, B., Wu, S., Garden, B.C., West, D.P., Reich, L.M. & Lacouture, M.E. (2013) Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clinical Lymphoma Myeloma & Leukemia, 13, 424-429.
5. Penna, G., Allegra, A., Romeo, G., Alonci, A., Cannavò, A., Russo, S., D'Angelo, A., Petrungaro, A. & Musolino, C. (2012) Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. Acta Oncologica, 51, 944-947.
6. Phillips, J., Kujawa, J., Davis-Lorton, M. & Hindenburg, A. (2007) Successful desensitization in a patient with lenalidomide hypersensitivity. American Journal of Hematology, 82, 1030.
7. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R., Eastern Cooperative Oncology Group. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology, 11, 29-37.
8. Richardson, P., Jagannath, S., Hussein, M., Berenson, J., Singhal, S., Irwin, D., Williams, S.F., Bensinger, W., Badros, A.Z., Vescio, R., Kenvin, L., Yu, Z., Olesnyckyj, M., Zeldis, J., Knight, R. & Anderson, K.C. (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood, 114, 772-778.
9. Seki, J.T., Banglawala, S., Lentz, E.M. & Reece, D.E. (2013) Desensitization to lenalidomide in a patient with relapsed multiple myeloma. Clinical Lymphoma Myeloma & Leukemia, 13, 162-165.
10. Sviggum, H.P., Davis, M.D., Rajkumar, S.V. & Dispenzieri, A. (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Archives of Dermatology, 142, 1298-1302.